Kristy A Warner1, Alexandra E Oklejas1, Alexander T Pearson2, Zhaocheng Zhang1, Weishing Wu3, Vasu Divi4, Christie Rodriguez-Ramirez1, Rogerio M Castilho5, Peter J Polverini5, Jacques E Nör6. 1. Department of Cariology, Restorative Sciences, Endodontics, University of Michigan School of Dentistry, Ann Arbor, MI 48109, USA. 2. Dept of Medicine, University of Chicago, USA. 3. Biomedical Research Core Facility, University of Michigan, Ann Arbor, MI, USA. 4. Department of Otolaryngology, Stanford University, Stanford, CA, USA. 5. Department of Periodontics and Oral Medicine, School of Dentistry, Ann Arbor, MI 48109, USA. 6. Department of Cariology, Restorative Sciences, Endodontics, University of Michigan School of Dentistry, Ann Arbor, MI 48109, USA; Department of Biomedical Engineering, University of Michigan College of Engineering, Ann Arbor, MI, USA; Department of Otolaryngology, University of Michigan School of Medicine, Ann Arbor, MI, USA; Comprehensive Cancer Center, University of Michigan, Ann Arbor, MI, USA. Electronic address: jenor@umich.edu.
Abstract
OBJECTIVES: Limited availability of validated human adenoid cystic carcinoma (ACC) cell lines has hindered the mechanistic understanding of the pathobiology of this malignancy and the development of effective therapies. The purpose of this work was to generate and characterize a human ACC cell line. MATERIAL AND METHODS: Immediately after surgery, a tumor fragment from a minor salivary gland from the tongue of a female Caucasian was minced, dissociated, and a single cell suspension was plated in fibronectin-coated flasks. A culture medium containing bovine brain extract and rhEGF was optimized for these cells. Whole exome sequencing was used to evaluate the presence of MYB-NFIB translocation. RESULTS: The University of Michigan-Human Adenoid Cystic Carcinoma (UM-HACC)-2A cells showed continuous growth in monolayers for at least 180 in vitro passages while maintaining epithelial morphology. Short-tandem repeat (STR) profiling confirmed a 100% match to patient DNA. Whole exome sequencing revealed the presence of the MYB-NFIB fusion in UM-HACC-2A cells, which was confirmed by PCR analysis. Western blots revealed high expression of epithelial markers (e.g. E-cadherin, EGFR, pan-cytokeratin) and proteins associated with ACC (e.g. c-Myb, p63). Developmental therapeutic studies showed that UM-HACC-2A cells were resistant to cisplatin (IC50 = 44.7 µM) while more responsive to paclitaxel (IC50 = 0.0006 µM). In a pilot study, we observed that UM-HACC-2A cells survived orthotopic transplantation into the submandibular gland. Notably, one of the mice injected with UM-HACC-2A cells exhibited lung metastasis after 6 months. CONCLUSION: UM-HACC-2A is a MYB-NFIB fusion-positive ACC cell line that is suitable for mechanistic and developmental therapeutics studies.
OBJECTIVES: Limited availability of validated humanadenoid cystic carcinoma (ACC) cell lines has hindered the mechanistic understanding of the pathobiology of this malignancy and the development of effective therapies. The purpose of this work was to generate and characterize a humanACC cell line. MATERIAL AND METHODS: Immediately after surgery, a tumor fragment from a minor salivary gland from the tongue of a female Caucasian was minced, dissociated, and a single cell suspension was plated in fibronectin-coated flasks. A culture medium containing bovine brain extract and rhEGF was optimized for these cells. Whole exome sequencing was used to evaluate the presence of MYB-NFIB translocation. RESULTS: The University of Michigan-HumanAdenoid Cystic Carcinoma (UM-HACC)-2A cells showed continuous growth in monolayers for at least 180 in vitro passages while maintaining epithelial morphology. Short-tandem repeat (STR) profiling confirmed a 100% match to patient DNA. Whole exome sequencing revealed the presence of the MYB-NFIB fusion in UM-HACC-2A cells, which was confirmed by PCR analysis. Western blots revealed high expression of epithelial markers (e.g. E-cadherin, EGFR, pan-cytokeratin) and proteins associated with ACC (e.g. c-Myb, p63). Developmental therapeutic studies showed that UM-HACC-2A cells were resistant to cisplatin (IC50 = 44.7 µM) while more responsive to paclitaxel (IC50 = 0.0006 µM). In a pilot study, we observed that UM-HACC-2A cells survived orthotopic transplantation into the submandibular gland. Notably, one of the mice injected with UM-HACC-2A cells exhibited lung metastasis after 6 months. CONCLUSION:UM-HACC-2A is a MYB-NFIB fusion-positive ACC cell line that is suitable for mechanistic and developmental therapeutics studies.
Authors: Jonathan W Shum; Ioannis Chatzistefanou; Mohammed Qaisi; Joshua E Lubek; Robert A Ord Journal: Oral Surg Oral Med Oral Pathol Oral Radiol Date: 2015-10-22
Authors: Robert B West; Christina Kong; Nicole Clarke; Thea Gilks; Joe S Lipsick; Hongbin Cao; Shirley Kwok; Kelli D Montgomery; Sushama Varma; Quynh-Thu Le Journal: Am J Surg Pathol Date: 2011-01 Impact factor: 6.394
Authors: Yoshitsugu Mitani; Jie Li; Pulivarthi H Rao; Yi-Jue Zhao; Diana Bell; Scott M Lippman; Randal S Weber; Carlos Caulin; Adel K El-Naggar Journal: Clin Cancer Res Date: 2010-08-11 Impact factor: 12.531
Authors: Philip J Stephens; Helen R Davies; Yoshitsugu Mitani; Peter Van Loo; Adam Shlien; Patrick S Tarpey; Elli Papaemmanuil; Angela Cheverton; Graham R Bignell; Adam P Butler; John Gamble; Stephen Gamble; Claire Hardy; Jonathan Hinton; Mingming Jia; Alagu Jayakumar; David Jones; Calli Latimer; Stuart McLaren; David J McBride; Andrew Menzies; Laura Mudie; Mark Maddison; Keiran Raine; Serena Nik-Zainal; Sarah O'Meara; Jon W Teague; Ignacio Varela; David C Wedge; Ian Whitmore; Scott M Lippman; Ultan McDermott; Michael R Stratton; Peter J Campbell; Adel K El-Naggar; P Andrew Futreal Journal: J Clin Invest Date: 2013-06-17 Impact factor: 14.808
Authors: Kristy A Warner; Felipe Nör; Gerson A Acasigua; Manoela D Martins; Zhaocheng Zhang; Scott A McLean; Matthew E Spector; Douglas B Chepeha; Joseph Helman; Michael J Wick; Christopher A Moskaluk; Rogerio M Castilho; Alexander T Pearson; Shaomeng Wang; Jacques E Nör Journal: Clin Cancer Res Date: 2016-03-02 Impact factor: 12.531
Authors: Joseph O Humtsoe; Hyun-Su Kim; Leilani Jones; James Cevallos; Philippe Boileau; Fengshen Kuo; Luc G T Morris; Patrick Ha Journal: Cancers (Basel) Date: 2022-04-30 Impact factor: 6.575
Authors: Renata Ferrarotto; Vasudha Mishra; Elad Herz; Adar Yaacov; Oz Solomon; Rami Rauch; Adi Mondshine; Maria Motin; Tal Leibovich-Rivkin; Matti Davis; Joel Kaye; Christopher R Weber; Le Shen; Alexander T Pearson; Ari J Rosenberg; Xiangying Chen; Alka Singh; Jon C Aster; Nishant Agrawal; Evgeny Izumchenko Journal: Cell Death Dis Date: 2022-08-05 Impact factor: 9.685
Authors: Charbel A Basset; Francesca Rappa; Rosario Barone; Ada Maria Florena; Rossana Porcasi; Everly Conway de Macario; Alberto J L Macario; Angelo Leone Journal: Int J Mol Sci Date: 2022-08-18 Impact factor: 6.208